Do I need
GLP tox studies
yet?
Most biotech founders ask this question too late — or worse, they assume the answer is yes and burn months and millions on studies that aren't required. This is the framework we use to answer it correctly the first time.
First, what GLP
actually means.
Most founders use "GLP" as a synonym for "good lab work" — but it's a specific regulatory standard with a precise definition. Understanding what it actually requires is the first step to knowing whether you need it.
GLP — Good Laboratory Practice — is a quality system specified by the FDA in 21 CFR Part 58 that governs the conduct of non-clinical safety studies intended to support regulatory submissions. It's about documentation, traceability, and reproducibility — not the quality of the science itself.
-
A regulatory quality system with documented SOPs, audit trails, and study director oversight.
-
Required for pivotal safety studies that go into IND, NDA, and BLA submissions.
-
About traceability — can FDA reconstruct exactly what happened in your study, by whom, and when?
-
A significant cost and time investment — GLP studies cost 2–5x non-GLP equivalents.
-
A measure of scientific quality. Non-GLP studies can be every bit as rigorous — they just aren't auditable to FDA standards.
-
Required for exploratory, mechanistic, or dose-ranging studies. These are typically non-GLP and that's appropriate.
-
The same as cGMP. GMP governs manufacturing; GLP governs non-clinical safety studies. They are separate systems.
-
A universally-required threshold. Whether you need GLP depends entirely on what FDA expects for your specific pathway and stage.
GLP isn't better science. It's documented, audit-ready science — and it only matters when FDA is going to be the audience.
Why FDA cares so much
about how the data
was generated.
GLP didn't exist in a vacuum. In the mid-1970s, FDA inspectors found that multiple major pharmaceutical companies were submitting safety data that couldn't be reproduced or verified — sometimes intentionally fabricated, more often poorly documented and impossible to audit.
"We couldn't tell whether the studies had been run as described, by qualified people, with proper controls. The data might have been correct — but we had no way to know." FDA Investigation, 1976 (Industrial BioTest scandal)
GLP exists to solve that auditability problem. It's why FDA doesn't just care that you ran a tox study — they care whether you can prove, in writing, that you ran it the way you said you ran it, by qualified people, with documented controls and quality oversight.
GLP is triggered by where the data goes — not what it costs to generate.
You need GLP if your study will be submitted to FDA to support a regulatory decision. Specifically:
-
01Pivotal IND-enabling toxicology studies — repeat-dose, genotoxicity, safety pharmacology, reproductive tox.
-
02Bridging studies for Section 505 submissions — when existing data needs to be bridged to your product.
-
03Biocompatibility testing under ISO 10993 — for medical device IDE and 510(k) submissions.
-
04Carcinogenicity, juvenile tox, or chronic studies — anything pivotal to label safety claims.
-
05Pharmacokinetic and TK studies when intended to support clinical dose selection in IND.
Answer these four
questions honestly.
These are the same questions Dr. Kamendi walks through in a Regulatory Roadmap Session. Your answers will tell you exactly where GLP fits — or doesn't — in your current plan.
Are you planning to file an IND or IDE submission
within the next 12 to 18 months?
GLP studies are almost certainly part of your path. The strategic question is which ones, at what dose, and in what species — not whether you need them. Pre-IND strategy work now will determine timeline and cost.
You likely don't need GLP yet. Non-GLP mechanistic and range-finding studies are appropriate at this stage. Running GLP now is almost certainly premature — and wasteful.
Is your molecule a New Molecular Entity, or
does substantial tox data already exist?
A full GLP toxicology package is typically required: 2-species repeat-dose, full genotoxicity battery, safety pharmacology, and TK. Timeline planning is critical — these studies take 6–12+ months and cost millions.
A bridging strategy may dramatically reduce your tox burden. Significant cost savings are possible — but only if existing data is correctly mapped against gaps. This is where strategy work pays for itself many times over.
Will your indication require chronic dosing,
a sensitive population, or device implantation?
Expect expanded GLP requirements: longer duration studies, juvenile or reproductive tox, biocompatibility per ISO 10993, or carcinogenicity assessments. Plan timeline and budget accordingly — these can add 12–24 months.
A standard GLP tox package is likely sufficient. Acute-to-subchronic studies in two species, plus genotoxicity, will typically support your IND. Focus on dose selection and species choice rather than scope expansion.
Have you had a Pre-IND meeting or written
FDA correspondence on your tox plan?
FDA has signaled what they expect. Your job is to execute against that guidance precisely — protocols should map directly to their stated expectations, with no scope creep and no shortcuts.
You are making major investment decisions on assumptions, not feedback. A Pre-IND meeting or Type B written request can save months of misaligned study work. Consider this before commissioning GLP work.